About ELMO domain-containing protein 3
ELMO domain-containing protein 3 (ELMOD3) is a protein
from Homo sapiens identified by UniProt accession
Q96FG2, 381 residues long.
MolForge cross-references it against 0 known binders and
53 disease associations.
Target properties
| Protein name | ELMO domain-containing protein 3 |
| UniProt accession | Q96FG2 |
| Gene | ELMOD3 |
| Organism | Homo sapiens |
| Length | 381 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (53)
Diseases linked to this target (Open Targets).
- hearing loss, autosomal recessive · score 0.46
- deafness · score 0.37
- bone density · score 0.10
- urate measurement · score 0.09
- high density lipoprotein cholesterol measurement · score 0.09
- attention deficit hyperactivity disorder · score 0.09
- mean platelet volume · score 0.08
- attention deficit-hyperactivity disorder 8 · score 0.07
- schizophrenia 15 · score 0.07
- lymphocyte percentage of leukocytes · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96FG2-F1 | alphafold | PREDICTED | 75.78 | — |
Amino-acid sequence (381 residues)
MNEKSCSFHS KEELRDGQGE RLSAGYSPSY DKDKSVLAFR GIPISELKNH GILQALTTEA YEWEPRVVST EVVRAQEEWE AVDTIQPETG SQASSEQPGQ LISFSEALQH FQTVDLSPFK KRIQPTIRRT GLAALRHYLF GPPKLHQRLR EERDLVLTIA QCGLDSQDPV HGRVLQTIYK KLTGSKFDCA LHGNHWEDLG FQGANPATDL RGAGFLALLH LLYLVMDSKT LPMAQEIFRL SRHHIQQFPF CLMSVNITHI AIQALREECL SRECNRQQKV IPVVNSFYAA TFLHLAHVWR TQRKTISDSG FVLKELEVLA KKSPRRLLKT LELYLARVSK GQASLLGAQK CYGPEAPPFK DLTFTGESDL QSHSSEGVWL I
Explore ELMO domain-containing protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets